Strong Diagnostics, Biosimilar Pain Expected In Roche Q1
Good New Medicine Sales Should Also Feature In Results
Investors during Roche’s first-quarter update 21 April will be looking for guidance on the strong growth of biosimilar competition to its cancer mainstays and how this may be offset by the group’s pipeline.
You may also be interested in...
Biosimilar erosion and slack drugs sales caused by the pandemic depressed Roche’s first quarter pharma revenue while its diagnostics unit saw sales soar on COVID testing.
Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.
GenMark’s syndromic panel testing portfolio complements Roche’s molecular diagnostics business.